

TENNESSEE

COLLEGE of MEDICINE


Mubeen Khan Mohammed Abdul, MD¹; Karim T. Osman, MD², Joseph M. Cappuccio, DO²; Carol Spencer, MSLS³; Satheesh Nair, MD⁴ ¹Advocate Aurora St Luke's Medical Center, Milwaukee, WI² Department of Internal Medicine, Lahey Clinic ³ Department of Library Services, Lahey Clinic⁴ Division of Transplant Hepatology, University of Tennessee Health Sciences

Introduction

- Nosocomial Spontaneous Bacterial Peritonitis (NSBP) incidence has be the rise due to frequent hospitalizations in the cirrhotic population alor rampant antibiotics use
- There has been a shift in the bacterial spectrum including resistance with emergence of Multi Drug Resistant Organisms
- The incidence of NSBP has not been studied
- Furthermore, the rate of resistance to first-line agents in management of is not well reported in NSBP
- Thus, we conducted a systematic review and meta-analysis of av literature.

Methods

- We conducted a comprehensive literature review of MEDLINE, EN Cochrane, and Scopus databases
- Studies included in the systematic review met the following inclusion adult patients, age >18 years, with a diagnosis of NSBP
- NSBP was diagnosed as SBP diagnosed after at least 48 ho hospitalization
- Exclusion criteria: Manuscripts with <5 patients, no report of prevale NSBP or the incidence of MDRO in NSBP
- Pooled estimates were calculated following the restricted maximum lik method using random effects model. Heterogeneity was reported as I^2



Epidemiological Data and Anti-Microbial Resistance of Nosocomial Spontaneous Bacterial Peritonitis: A **Systematic Review and Meta-Analysis**

| Study (Year) | Age (years) | Number of patients with cirrhosis | Number of patients with NSBP | Number of patients resistant to third generation cephalosporins | Number of patient resistant to Fluoroquinoles |
|-----------------------------|---------------------|---|------------------------------------|---|---|
| Friedrich et al (2015 |) 57 | 311 | 218 | Not specified (NS) | NS |
| Salerno et al (2016) | NS | 308 | 24 | NS | NS |
| Shultablers et al (2020) | 56±11 | 514 | 127 | NS | NS |
| Balaraju et al (2017) | 48.4±14 | 706 | 21 | NS | NS |
| Jain et al (2019) | 48 (29-71) | 870 | 19 | NS | NS |
| Kim et al (2012) | 50.1±9.4 | 130 | 19 | 1 | NS |
| Kimmann et al (2018) | 56 (49-63) | 1011 | 203 | NS | NS |
| Song et al (2006) | 58 (8.7) | 106 | 32 | 14 | 8 |
| Lan Juan Li et al (2015) | 55 (23-79) | 6086 | 65 | 11 | 19 |
| Elshamy et al (2022 |) 45 (30-80) | NS | 68 | 13 | 12 |
| Lutz et al (2016) | 59 (51-69) | NS | 63 | 9 | 14 |
| Bert et al (2003) | 50 (26-80) | NS | 53 | 13 | 22 |
| Ding et al (2019) | 56.3±10.3 | NS | 155 | 27 | 23 |
| Chon et al (2014) | NS | NS | NS | NS | NS |
| Piroth et al (2014) | NS | 1659 | NS | 72 | 62 |


Figure 2. Prevalence of NSBP

Study

Song 2006 Lan Juan Li 2015 Freidrich 2015 Salerno et al 2016 Schultalbers 2020 Balaraju 2017 Jain 2019 Kim 2012 Kimmann 2018 Li 2015 Piroth 2014

Random effects model

Event Rate



Results

Beth Israel Lahey Health Lahey Hospital & Medical Center

- Figure 1 shows the flowchart of identifying relevant articles
- **Table 1** summarizes the study characteristics
- The pooled incidence of NSBP was 9.45% [95%] confidence interval (CI) 3.82-21.49%; I² 99.40%] (**Figure** 2)
- The pooled clinical success rate was 82.32% (95% CI 74.90-87.89%, I²0)
- The pooled incidence of resistance to ceftriaxone was 27.72% (95% CI 2.13-35.26%; I² 84.52%)
- The pooled incidence of resistance to fluoroquinolones was 24.71% (95% CI 18.19-32.64%; I² 80.25%)

Discussion

- The incidence of NSBP in patients with cirrhosis is relatively high
- The rates of bacterial resistance to the first-line antimicrobial agents used to treat SBP (i.e., ceftriaxone/fluoroquinolones) is exceptionally high in this patient population
- Thus, in patients with NSBP who fail to improve, providers should have a high level of suspicion for drug-resistance being a contributing factor
- Furthermore, the high resistance rates to fluoroquinolones in NSBP should be taken into consideration when placing this patient population on secondary prophylaxis.